Production of recombinant proteins in milk of transgenic and non-transgenic goats

Moura, R.R.; Melo, Luciana Magalhães; Freitas, Vicente José de Figueirêdo

doi:10.1590/s1516-89132011000500010

Cited by 19 publications

(10 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Collectively, our data not only provides new insights regarding miRNAs participation in the gene network controlling milk fat synthesis, but also gives us important clues that miR-103 may be used as an index for a molecular breeding program in goats. Furthermore, transgenic goats have been reported to secrete milk containing lactoferrin, α-fetoprotein, and lysozymes [91] , [92] , [93] . These successes in goats provide important clues that over-expression of certain component are feasible in the mammary gland.…”

Section: Discussionmentioning

confidence: 99%

MiR-103 Controls Milk Fat Accumulation in Goat (Capra hircus) Mammary Gland during Lactation

et al. 2013

View full text Add to dashboard Cite

Milk is the primary source of nutrition for young mammals including humans. The nutritional value of milk is mainly attributable to fats and proteins fractions. In comparison to cow milk, goat milk contains greater amounts of total fat, including much higher levels of the beneficial unsaturated fatty acids. MicroRNAs (miRNAs), a well-defined group of small RNAs containing about 22 nucleotides (nt), participate in various metabolic processes across species. However, little is known regarding the role of miRNAs in regulating goat milk composition. In the present study, we performed high-throughput sequencing to identify mammary gland-enriched miRNAs in lactating goats. We identified 30 highly expressed miRNAs in the mammary gland, including miR-103. Further studies revealed that miR-103 expression correlates with the lactation. Further functional analysis showed that over-expression of miR-103 in mammary gland epithelial cells increases transcription of genes associated with milk fat synthesis, resulting in an up-regulation of fat droplet formation, triglyceride accumulation, and the proportion of unsaturated fatty acids. This study provides new insight into the functions of miR-103, as well as the molecular mechanisms that regulate milk fat synthesis.

show abstract

Section: Discussionmentioning

confidence: 99%

MiR-103 Controls Milk Fat Accumulation in Goat (Capra hircus) Mammary Gland during Lactation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Thus, conestat alfa (brand name Ruconest), a recombinant analogue of the human esterase inhibitor C1, was approved for the treatment of hereditary angioedema . The recombinant proteins produced by these animals are secreted into their milk .…”

Section: Systems For the Production Of Biopharmaceuticalsmentioning

confidence: 99%

Progress in biopharmaceutical development

Kęsik-Brodacka

2017

Biotech and App Biochem

267

126

View full text Add to dashboard Cite

Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed.

show abstract

“…Transgenic animals possess a transgene coding a recombinant protein that is integrated into their genome, and they are capable of passing it on to their offspring. Nowadays, the ways of sourcing proteins include milk from transgenic mammals and eggs from transgenic chickens (Moura et al, 2011;Maksimenko et al, 2013;Owczarek et al, 2019). The natural secretion of recombinant proteins occurs in this system and provides the correct PTMs.…”

Section: Transgenic Animalsmentioning

confidence: 99%

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

Tripathi

Shrivastava

2019

Front. Bioeng. Biotechnol.

400

243

View full text Add to dashboard Cite

Infectious diseases, along with cancers, are among the main causes of death among humans worldwide. The production of therapeutic proteins for treating diseases at large scale for millions of individuals is one of the essential needs of mankind. Recent progress in the area of recombinant DNA technologies has paved the way to producing recombinant proteins that can be used as therapeutics, vaccines, and diagnostic reagents. Recombinant proteins for these applications are mainly produced using prokaryotic and eukaryotic expression host systems such as mammalian cells, bacteria, yeast, insect cells, and transgenic plants at laboratory scale as well as in large-scale settings. The development of efficient bioprocessing strategies is crucial for industrial production of recombinant proteins of therapeutic and prophylactic importance. Recently, advances have been made in the various areas of bioprocessing and are being utilized to develop effective processes for producing recombinant proteins. These include the use of high-throughput devices for effective bioprocess optimization and of disposable systems, continuous upstream processing, continuous chromatography, integrated continuous bioprocessing, Quality by Design, and process analytical technologies to achieve quality product with higher yield. This review summarizes recent developments in the bioprocessing of recombinant proteins, including in various expression systems, bioprocess development, and the upstream and downstream processing of recombinant proteins.

show abstract

Production of recombinant proteins in milk of transgenic and non-transgenic goats

Cited by 19 publications

References 67 publications

MiR-103 Controls Milk Fat Accumulation in Goat (Capra hircus) Mammary Gland during Lactation

MiR-103 Controls Milk Fat Accumulation in Goat (Capra hircus) Mammary Gland during Lactation

Progress in biopharmaceutical development

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

Contact Info

Product

Resources

About